Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MicroScale system integrating Patient-specific cancer Organoids in a 3D Tumor microenvironment for Therapy rEsponse preDiction

Project description

3D tumour models for personalised pancreatic cancer therapy

The tumour microenvironment (TME) comprises a complex network of stroma, immune cells, and extracellular matrix (ECM) components that contribute to cancer progression and affect treatment response. Existing in vitro cancer models do not faithfully mimic the TME, limiting progress in personalised medicine. The ERC-funded SPOTTED project addresses this gap by developing patient-derived, 3D pancreatic cancer models integrated into a microfluidic platform. The proposed system will combine organoids and ECM hydrogels to replicate the native architecture of tumours. The rationale is to use them for high-throughput drug testing to improve predictive accuracy and accelerate therapy development for pancreatic and other solid cancers.

Objective

Cancer remains a leading global cause of death, with incidence projected to increase significantly by 2050. Despite advances in detection and treatment, there is an urgent need for more effective and personalized therapies. Personalized medicine (PM) is emerging as the future of cancer care, using 3D patient-specific models to replicate the tumors complexity. Current in vitro models struggle to accurately mimic the tumor microenvironment (TME), including the extracellular matrix (ECM) and stromal interactions, which are critical to tumor progression and therapy response.
SPOTTED aims to address these limitations by developing patient-derived (PD) in vitro models integrated into a microfluidic device, by exploiting patient-derived organoids (PDOs) from bioptic tissues from the Biobanca di Ricerca of the University Hospital of Padua. The first vertical case study is on pancreatic cancer (PC), projected to become the second deadliest type of solid tumor by 2040. Our SPOTTED platform will use PDOs and PD-ECM hydrogels to reconstruct a realistic 3D model of PC, incorporating stromal and immune cells. By replicating the TME, SPOTTED enables precise drug screening and therapeutic testing in a highly controlled and automated environment. Its design allows for real-time monitoring and analysis, while the platform’s versatility supports scalable, reproducible experiments tailored to individual patients.
SPOTTED, with its customizable, patient-specific approach, aims to bridge the gap between laboratory research and clinical application, paving the way for more effective, tailored therapies for PC and other solid tumors, with the potential to revolutionize personalized cancer treatment.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITA DEGLI STUDI DI PADOVA
Net EU contribution
€ 150 000,00
Address
VIA 8 FEBBRAIO 2
35122 Padova
Italy
Region
Nord-Est Veneto Padova
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)